India, Aug. 8 -- While reporting financial results for the third quarter on Friday, diabetes management company Embecta Corp. (EMBC), which was spun-off from medical technology company Becton, Dickinson and Co. (BDX), raised its adjusted earnings guidance for the full-year 2025, while tightening annual revenue outlook range.
For fiscal 2025, the company now projects adjusted earnings in a range of $2.90 to $2.95 per share on revenues between $1.078 billion and $1.085 billion.
Previously, the company expected adjusted earnings in a range of $2.70 to $2.90 per share on revenues between $1.073 billion and $1.090 billion.
On average, four analysts polled expect the company to report earnings of $2.83 per share on revenues of $1.08 billion fo...